抑制LNK(SH2B3)可扩增健康及范可尼贫血人造血干/祖细胞
研究通过慢病毒表达miR30短发夹RNA敲低LNK,实现可移植人造血干细胞稳健扩增并在小鼠体内多系重建;LNK缺失增强CD34+细胞JAK/STAT活化,并改善范可尼贫血样及患者来源造血干/祖细胞的植入与集落形成能力。
要点
- 敲低LNK可稳健扩增可移植人造血干细胞,并在原发和继发小鼠受体中实现平衡多系重建。
- LNK缺失增强CD34+造血干/祖细胞中细胞因子介导的JAK/STAT活化。
- 抑制LNK改善FANCD2敲低范可尼贫血样造血干细胞的异种移植植入,并增强范可尼贫血患者骨髓造血干/祖细胞的体外集落形成潜能。
核心结论
- 靶向LNK以扩增造血干细胞有望改善造血干细胞移植及基于移植的基因治疗。
研究设计与样本
- 通过慢病毒表达miR30短发夹RNA敲低LNK,在CD34+造血干/祖细胞及范可尼贫血患者骨髓标本中开展体外与异种移植实验。
主要发现
- LNK敲低使可移植人造血干细胞稳健扩增,并在原发和继发小鼠受体中提供平衡多系重建。
- LNK敲低增强CD34+造血干/祖细胞中细胞因子介导的JAK/STAT活化。
- LNK敲低扩增范可尼贫血相关原代造血干/祖细胞。
- 异种移植中,抑制LNK使FANCD2敲低的范可尼贫血样造血干细胞植入明显改善。
- 靶向范可尼贫血患者原代骨髓造血干/祖细胞的LNK增强其体外集落形成潜能。
临床怎么用
- 原文结论指出靶向LNK扩增造血干细胞有望改善造血干细胞移植及基于移植的基因治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for a variety of hematological diseases. Allogenic HSCT requires hematopoietic stem cells (HSCs) from matched donors and comes with cytotoxicity and mortality. Recent advances in genome modification of HSCs have demonstrated the possibility of using autologous HSCT-based gene therapy to alleviate hematologic symptoms in monogenic diseases, such as the inherited bone marrow failure (BMF) syndrome Fanconi anemia (FA). However, for FA and other BMF syndromes, insufficient HSC numbers with functional defects results in delayed hematopoietic recovery and increased risk of graft failure. We and others previously identified the adaptor protein LNK (SH2B3) as a critical negative regulator of murine HSC homeostasis. However, whether LNK controls human HSCs has not been studied. Here, we demonstrate that depletion of LNK via lentiviral expression of miR30-based short hairpin RNAs results in robust expansion of transplantable human HSCs that provided balanced multilineage reconstitution in primary and secondary mouse recipients. Importantly, LNK depletion enhances cytokine-mediated JAK/STAT activation in CD34+ hematopoietic stem and progenitor cells (HSPCs). Moreover, we demonstrate that LNK depletion expands primary HSPCs associated with FA. In xenotransplant, engraftment of FANCD2-depleted FA-like HSCs was markedly improved by LNK inhibition. Finally, targeting LNK in primary bone marrow HSPCs from FA patients enhanced their colony forming potential in vitro. Together, these results demonstrate the potential of targeting LNK to expand HSCs to improve HSCT and HSCT-based gene therapy.
引用
- Holdreith N, Lee G, Chandra V, et al. LNK (SH2B3) inhibition expands healthy and Fanconi anemia human hematopoietic stem and progenitor cells. Blood Adv. 2022. PMID: 34844262. doi:10.1182/bloodadvances.2021004205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。